Inhibitor Therapeutics, INC
Market Movers (8-K)
OQB
Inhibitor Therapeutics provided an update on its itraconazole program for Gorlin Syndrome, detailing clinical progress, formulation strategy, and plans for a new global patent filing.
OQB
Inhibitor Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor for a $3 million private placement, issuing common stock and warrants.
Capital raise
Delay expected
OQB
Inhibitor Therapeutics, Inc. entered into a master services agreement with Frameshift Management for biostatistics and regulatory consulting and approved its 2025 Equity Incentive Plan, reserving 20 million shares.
Capital raise
Quarterly Earnings (10-Q)
OQB
Inhibitor Therapeutics reports Q1 2026 net loss of $0.69 million and faces going concern uncertainty following a failed $3 million capital raise.
Worse than expected
Capital raise
OQB
Inhibitor Therapeutics, Inc. reported an increased nine-month net loss and a significant decline in cash reserves, signaling potential future capital needs despite progress in drug development.
Worse than expected
Capital raise
OQB
Inhibitor Therapeutics reported a wider net loss and decreased cash in Q2 2025 as it advances its itraconazole drug development for cancer.
Worse than expected
Capital raise
Delay expected
OQB
Inhibitor Therapeutics reports a net loss for Q1 2025 while progressing with its plan to develop itraconazole-based therapies.
Capital raise
OQB
10-Q: Inhibitor Therapeutics Reports Third Quarter 2024 Financial Results, Progresses FDA Discussions
Inhibitor Therapeutics reports its financial results for the third quarter of 2024, highlighting ongoing efforts in drug development and regulatory engagement with the FDA.
Worse than expected
Delay expected
Capital raise
OQB
Inhibitor Therapeutics reported its financial results for the second quarter of 2024, highlighting ongoing research and development efforts and preparations for a key meeting with the FDA regarding its itraconazole-based cancer therapies.
Capital raise
Annual Reports (10-K)
OQB
Inhibitor Therapeutics' 2024 annual report highlights ongoing efforts to develop itraconazole-based therapies for various cancers, with a focus on regulatory pathways and strategic partnerships.
Delay expected
Worse than expected
OQB
Inhibitor Therapeutics, a pharmaceutical development company, released its 2023 annual report, highlighting progress in its cancer therapy development and a new licensing agreement with Johns Hopkins University.
Capital raise
Worse than expected
Insider Trading (Form 4)
OQB
Ronald E Osman and 1 other reported changes in beneficial ownership of Inhibitor Therapeutics, Inc. common stock on May 4, 2026.
OQB
Michelle Yanez, a Director of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
OQB
Samuel P Sears Jr, a Director of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
OQB
Francis E Odonnell Jr, Chief Executive Officer, a Director and 10% owner of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
OQB
Michael Jerman, a Director at Inhibitor Therapeutics, Inc., was issued 50,000 shares of common stock as compensation on May 4, 2026.
OQB
Niraj Vasisht, a Director at Inhibitor Therapeutics, Inc., acquired 50,000 shares of common stock as compensation.